Prostate Specific Antigen News and Research RSS Feed - Prostate Specific Antigen News and Research

New model can increase active surveillance for low-risk prostate cancer patients

New model can increase active surveillance for low-risk prostate cancer patients

Urologists at University of California, San Diego School of Medicine and Genesis Healthcare Partners have tested a new model of care for patients with low-risk prostate cancer. The evidence-based approach uses best practices to appropriately select and follow patients to avoid disease overtreatment. Results of the three-year study are now published online in the journal of Urology. [More]
CWRU scientists develop computational tools to quantify effects of prostate cancer laser ablation

CWRU scientists develop computational tools to quantify effects of prostate cancer laser ablation

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated. Or they're serious enough to require surgery and radiation. [More]
Experimental urine test identifies 92% of men with elevated PSA levels

Experimental urine test identifies 92% of men with elevated PSA levels

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online. [More]
ANGLE’s Parsortix system may be used for detection of prostate cancer, Barts patient data suggests

ANGLE’s Parsortix system may be used for detection of prostate cancer, Barts patient data suggests

ANGLE plc, the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute’s ongoing work with ANGLE’s Parsortix system have provided evidence in support of the use of Parsortix in the detection and assessment of prostate cancer. [More]
ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). [More]
CWRU researcher to customize tobacco mosaic virus to treat human cancers

CWRU researcher to customize tobacco mosaic virus to treat human cancers

A Case Western Reserve University researcher has been awarded more than $3 million in federal and foundation grants to turn common plant viruses into cancer sleuths and search-and-destroy emissaries. [More]
Active surveillance recommended for low-risk prostate cancer

Active surveillance recommended for low-risk prostate cancer

For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society of Clinical Oncology. [More]
ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

Advances in Radiation Oncology, ASTRO's new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy. [More]
New biosensor test system developed for accurate measurements of protein molecule concentration in blood

New biosensor test system developed for accurate measurements of protein molecule concentration in blood

Researchers from the General Physics Institute of the Russian Academy of Sciences and Moscow Institute of Physics and Technology have developed a new biosensor test system based on magnetic nanoparticles. [More]
Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology. [More]

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. [More]
Men not having important discussions with health providers about prostate cancer screening, treatment

Men not having important discussions with health providers about prostate cancer screening, treatment

Researchers at the University of Nebraska Medical Center and the University of Memphis recently published an article in the American Journal of Men's Health which found that men and their health providers are not having important discussions when it comes to prostate cancer screening and treatment. [More]
Study supports argument that declining PSA screening may lead to avoidable cancer deaths

Study supports argument that declining PSA screening may lead to avoidable cancer deaths

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for two and a half years. Although the number of prostate needle biopsies (PNB) has been reduced, patients who undergo PNB are significantly more likely to be diagnosed with high risk disease, and detection of intermediate risk, potentially curable PCa has likely decreased. [More]
African American men with prostate cancer have significantly lower PSA density than Caucasian men

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs. [More]
Repeating abnormal PSA tests can reduce unnecessary biopsies

Repeating abnormal PSA tests can reduce unnecessary biopsies

For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer, but in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies. [More]
Two studies find decline in PSA screening and prostate cancer incidence

Two studies find decline in PSA screening and prostate cancer incidence

Two studies in the November 17 issue of JAMA examine the change in prostate-specific antigen (PSA) screening and prostate cancer incidence before and after the 2012 U.S. Preventive Services Task Force (USPSTF) screening recommendations. [More]
PSA screening for prostate cancer drops significantly in middle-aged men

PSA screening for prostate cancer drops significantly in middle-aged men

PSA testing has dropped significantly in middle-aged men after a 2012 recommendation that all men should not be routinely screened for prostate cancer, according to a new study published in the Journal of the American Medical Association. [More]
EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan. [More]
Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. [More]
USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial. While it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology. [More]
Advertisement
Advertisement